highly significantp < 0.0001
From baseline (day 0) to the end of DB (day 84), the severity of headache/migraine decreased by −1.6 ± 0.9 (-2.0) points in the ERr 731® group and by −0.2 ± 0.8 [0,0] points in the placebo group resulting in a highly significant difference ( p < 0.0001) in the severity as well as in the decrease of symptoms between the two treatment groups ( Figure 2 ).